Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study

References

• Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516–28.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258–65.
   PubMed Web of Science ®Google Scholar
• The National Health Care Institute (Zorginstituut Nederland). Price information, in Dutch (www.medicijnkosten.nl). Accessed 29 April 2019.
   Google Scholar
• Fautrel B, Den Broeder AA. De-intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol 2015;29:550–65.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Sinigaglia L, Cazzato M, Gremiale RD, Triolo G, Lubrano E, et al. Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. Rheumatology (Oxford) 2018;57:vii23–31.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, Den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014:CD010455.
   PubMed Web of Science ®Google Scholar
• Verhoef LM, Tweehuysen L, Hulscher ME, Fautrel B, den Broeder AA. bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search. Rheumatol Ther 2017;4:1–24.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59–67.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, van der Maas A, Minten MJ, van Den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389.
   PubMed Web of Science ®Google Scholar
• Kievit W, van Herwaarden N, van Den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis 2016;75:1939–44.
   PubMed Web of Science ®Google Scholar
• Vanier A, Mariette X, Tubach F, Fautrel B. Cost-effectiveness of TNF-blocker injection spacing for patients with established rheumatoid arthritis in remission: an economic evaluation from the spacing of TNF-blocker injections in rheumatoid arthritis trial. Value Health 2017;20:577–85.
   PubMed Web of Science ®Google Scholar
• Galvao TF, Zimmermann IR, Da Mota LM, Silva MT, Pereira MG. Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2016;35:1659–68.
   PubMed Web of Science ®Google Scholar
• van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800–5.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van Den Ende CH, Beeren FM, Been EM, van Den Hoogen FH, Den Broeder AA. Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review. Arthritis Rheumatol 2017;69:301–8.
   PubMed Web of Science ®Google Scholar
• Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9:110–18.
   PubMedGoogle Scholar
• Welsing PM, Severens JL, Hartman M, van Gestel AM, van Riel PL, Laan RF. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics 2006;24:1011–20.
   PubMed Web of Science ®Google Scholar
• Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl 2004;69:14–21.
   PubMedGoogle Scholar
• Versteegh M, Vermeulen M, Evers AA, de Wit GA, Prenger R, Stolk A. Dutch tariff for the five-level version of EQ-5D. Value Health 2016;19:343–52.
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Making 2012;32:678–89.
   PubMed Web of Science ®Google Scholar
• Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van Roijen L. Update of the Dutch manual for costing studies in health care. PLoS One 2017;12:e0187477.
   PubMed Web of Science ®Google Scholar
• Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics 2018;36:745–58.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care 2011;27:71–6.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force–6. Value Health 2012;15:835–42.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making 2012;32:667–77.
   PubMed Web of Science ®Google Scholar
• Vemer P, Corro RI, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics 2016;34:349–61.
   PubMed Web of Science ®Google Scholar
• Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571–82.
   PubMed Web of Science ®Google Scholar
• Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523–32.
   PubMed Web of Science ®Google Scholar
• Ferriols-Lisart R, Ferriorl-Lisart F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol Int 2015;35:1193–210.
   PubMed Web of Science ®Google Scholar